| | 405169-16-6 Basic information More.. |
| Product Name: | Dovitinib | | Synonyms: | 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;dovitinib;Unii-I35H55G906;CHIR258 7.7G;TKI-258;4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;CHIR-258(Dovitinib,TKI258);CHIR-258(Dovitinib) | | CAS: | 405169-16-6 | | MF: | C21H21FN6O | | MW: | 392.43 | | EINECS: | 1308068-626-2 | | Mol File: | 405169-16-6.mol |  |
Use
Dovitinib is a receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor-2, basic fibroblast growth factor-1, and platelet-derived growth factor β receptors (IC50s = 65, 11, and 5 nM, respectively). At 0.04 μM, dovitinib can inhibit endothelial cell proliferation and motility. These antiangiogenic effects have been proposed to be the mechanism by which dovitinib inhibits hepatocellular carcinoma growth and metastasis. Dovitinib has been evaluated in clinical trials for the treatment of advanced solid tumors.
Dovitinib is a receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor-2, basic fibroblast growth factor-1, and platelet-derived growth factor β receptors (IC50s = 65, 11, and 5 nM, respectively). At 0.04 μM, dovitinib can inhibit endothelial cell proliferation and motility. These antiangiogenic effects have been proposed to be the mechanism by which dovitinib inhibits hepatocellular carcinoma growth and metastasis. Dovitinib has been evaluated in clinical trials for the treatment of advanced solid tumors.
- Dovitinib
-
- US $0.00-0.00 / kg
- 2023-12-29
- CAS:405169-16-6
- Min. Order: 1kg
- Purity: 99%, Single impurity＜0.1
- Supply Ability: 1 ton
- CHIR-258(Dovitinib,TKI258)
-
- US $0.00-0.00 / bottle
- 2022-06-25
- CAS:405169-16-6
- Min. Order: 1bottle
- Purity: 98%
- Supply Ability: 100 bottles
|
|
405169-16-6
Recommend Suppliers |
|